Industry news
AstraZeneca rejects latest Pfizer offer
The Board of AstraZeneca PLC notes the announcement made by Pfizer Inc.. Pfizer’s announcement contains no new proposal nor substantive new information. The Board of AstraZeneca believes Pfizer is making an opportunistic attempt to acquire a transformed AstraZeneca, without reflecting the value of its exciting pipeline. This value should accrue fully to AstraZeneca shareholders. The Board reiterates its confidence in AstraZeneca’s ability to deliver on its prospects as an independent, science led business.